The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours

A pilot study

Chang Chang Ting, Chen Yen Tzu, Tai Li Yiu, Ching Wu Yen, Cheng Chang Yu, Kwan Ng Koon, Ming Jung Shih, I. Wu Tzu, Huey Lai Chyong

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: We conducted a pilot trial to evaluate the value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in gestational trophoblastic tumours (GTTs). Methods: Patients with placental site trophoblastic tumour (PSTT), high-risk GTT (World Health Organisation score ≥8, disease onset at postpartum or greater than 6 months after antecedent pregnancy), metastatic GTT, recurrent/resistant GTT after chemotherapy, or post-molar GTT with unexplained abnormal β-hCG regression and patients undergoing re-evaluation after salvage treatment were enrolled. PET was undertaken within 1 week after computed tomography (CT). Clinical impacts of additional PET were determined on a scan basis. Results: A total of 14 patients were recruited. Sixteen PET scans were performed, with one patient having three serial studies. Benefits of additional PET were seen in 7 of 16 (43.8%) scans; these benefits included disclosure of chemotherapy-resistant lesions (n=2), exclusion of false-positive CT lesions (n=1), detection of an additional lesion not found by conventional imaging (n=1) in high-risk GTT at the start of primary chemotherapy, and confirmation of complete response to treatment for PSTT or to salvage therapy for recurrent/resistant GTT (n=3). On the other hand, in two instances there were false-negative PET findings, six scans yielded no benefit, and one showed an indeterminate lesion. Conclusion: Our preliminary results suggest that 18F-FDG PET is potentially useful in selected patients with GTT by providing precise mapping of metastases and tumour extent upfront, by monitoring treatment response and by localising viable tumours after chemotherapy. A larger study is necessary to further define the role of 18F-FDG PET in GTT.

Original languageEnglish
Pages (from-to)156-163
Number of pages8
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume33
Issue number2
DOIs
Publication statusPublished - Feb 2006
Externally publishedYes

Fingerprint

Trophoblastic Neoplasms
Fluorodeoxyglucose F18
Positron-Emission Tomography
Placental Site Trophoblastic Tumor
Drug Therapy
Salvage Therapy
Tomography
Disclosure
Postpartum Period
Neoplasms
Neoplasm Metastasis

Keywords

  • β-hCG
  • F-FDG
  • Chemoresistant
  • Gestational trophoblastic tumour
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours : A pilot study. / Ting, Chang Chang; Tzu, Chen Yen; Yiu, Tai Li; Yen, Ching Wu; Yu, Cheng Chang; Koon, Kwan Ng; Shih, Ming Jung; Tzu, I. Wu; Chyong, Huey Lai.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 33, No. 2, 02.2006, p. 156-163.

Research output: Contribution to journalArticle

Ting, Chang Chang ; Tzu, Chen Yen ; Yiu, Tai Li ; Yen, Ching Wu ; Yu, Cheng Chang ; Koon, Kwan Ng ; Shih, Ming Jung ; Tzu, I. Wu ; Chyong, Huey Lai. / The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours : A pilot study. In: European Journal of Nuclear Medicine and Molecular Imaging. 2006 ; Vol. 33, No. 2. pp. 156-163.
@article{b2b1faed9764449aad27e7c51c877cc5,
title = "The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours: A pilot study",
abstract = "Purpose: We conducted a pilot trial to evaluate the value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in gestational trophoblastic tumours (GTTs). Methods: Patients with placental site trophoblastic tumour (PSTT), high-risk GTT (World Health Organisation score ≥8, disease onset at postpartum or greater than 6 months after antecedent pregnancy), metastatic GTT, recurrent/resistant GTT after chemotherapy, or post-molar GTT with unexplained abnormal β-hCG regression and patients undergoing re-evaluation after salvage treatment were enrolled. PET was undertaken within 1 week after computed tomography (CT). Clinical impacts of additional PET were determined on a scan basis. Results: A total of 14 patients were recruited. Sixteen PET scans were performed, with one patient having three serial studies. Benefits of additional PET were seen in 7 of 16 (43.8{\%}) scans; these benefits included disclosure of chemotherapy-resistant lesions (n=2), exclusion of false-positive CT lesions (n=1), detection of an additional lesion not found by conventional imaging (n=1) in high-risk GTT at the start of primary chemotherapy, and confirmation of complete response to treatment for PSTT or to salvage therapy for recurrent/resistant GTT (n=3). On the other hand, in two instances there were false-negative PET findings, six scans yielded no benefit, and one showed an indeterminate lesion. Conclusion: Our preliminary results suggest that 18F-FDG PET is potentially useful in selected patients with GTT by providing precise mapping of metastases and tumour extent upfront, by monitoring treatment response and by localising viable tumours after chemotherapy. A larger study is necessary to further define the role of 18F-FDG PET in GTT.",
keywords = "β-hCG, F-FDG, Chemoresistant, Gestational trophoblastic tumour, PET",
author = "Ting, {Chang Chang} and Tzu, {Chen Yen} and Yiu, {Tai Li} and Yen, {Ching Wu} and Yu, {Cheng Chang} and Koon, {Kwan Ng} and Shih, {Ming Jung} and Tzu, {I. Wu} and Chyong, {Huey Lai}",
year = "2006",
month = "2",
doi = "10.1007/s00259-005-1873-1",
language = "English",
volume = "33",
pages = "156--163",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours

T2 - A pilot study

AU - Ting, Chang Chang

AU - Tzu, Chen Yen

AU - Yiu, Tai Li

AU - Yen, Ching Wu

AU - Yu, Cheng Chang

AU - Koon, Kwan Ng

AU - Shih, Ming Jung

AU - Tzu, I. Wu

AU - Chyong, Huey Lai

PY - 2006/2

Y1 - 2006/2

N2 - Purpose: We conducted a pilot trial to evaluate the value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in gestational trophoblastic tumours (GTTs). Methods: Patients with placental site trophoblastic tumour (PSTT), high-risk GTT (World Health Organisation score ≥8, disease onset at postpartum or greater than 6 months after antecedent pregnancy), metastatic GTT, recurrent/resistant GTT after chemotherapy, or post-molar GTT with unexplained abnormal β-hCG regression and patients undergoing re-evaluation after salvage treatment were enrolled. PET was undertaken within 1 week after computed tomography (CT). Clinical impacts of additional PET were determined on a scan basis. Results: A total of 14 patients were recruited. Sixteen PET scans were performed, with one patient having three serial studies. Benefits of additional PET were seen in 7 of 16 (43.8%) scans; these benefits included disclosure of chemotherapy-resistant lesions (n=2), exclusion of false-positive CT lesions (n=1), detection of an additional lesion not found by conventional imaging (n=1) in high-risk GTT at the start of primary chemotherapy, and confirmation of complete response to treatment for PSTT or to salvage therapy for recurrent/resistant GTT (n=3). On the other hand, in two instances there were false-negative PET findings, six scans yielded no benefit, and one showed an indeterminate lesion. Conclusion: Our preliminary results suggest that 18F-FDG PET is potentially useful in selected patients with GTT by providing precise mapping of metastases and tumour extent upfront, by monitoring treatment response and by localising viable tumours after chemotherapy. A larger study is necessary to further define the role of 18F-FDG PET in GTT.

AB - Purpose: We conducted a pilot trial to evaluate the value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in gestational trophoblastic tumours (GTTs). Methods: Patients with placental site trophoblastic tumour (PSTT), high-risk GTT (World Health Organisation score ≥8, disease onset at postpartum or greater than 6 months after antecedent pregnancy), metastatic GTT, recurrent/resistant GTT after chemotherapy, or post-molar GTT with unexplained abnormal β-hCG regression and patients undergoing re-evaluation after salvage treatment were enrolled. PET was undertaken within 1 week after computed tomography (CT). Clinical impacts of additional PET were determined on a scan basis. Results: A total of 14 patients were recruited. Sixteen PET scans were performed, with one patient having three serial studies. Benefits of additional PET were seen in 7 of 16 (43.8%) scans; these benefits included disclosure of chemotherapy-resistant lesions (n=2), exclusion of false-positive CT lesions (n=1), detection of an additional lesion not found by conventional imaging (n=1) in high-risk GTT at the start of primary chemotherapy, and confirmation of complete response to treatment for PSTT or to salvage therapy for recurrent/resistant GTT (n=3). On the other hand, in two instances there were false-negative PET findings, six scans yielded no benefit, and one showed an indeterminate lesion. Conclusion: Our preliminary results suggest that 18F-FDG PET is potentially useful in selected patients with GTT by providing precise mapping of metastases and tumour extent upfront, by monitoring treatment response and by localising viable tumours after chemotherapy. A larger study is necessary to further define the role of 18F-FDG PET in GTT.

KW - β-hCG

KW - F-FDG

KW - Chemoresistant

KW - Gestational trophoblastic tumour

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=31444456438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444456438&partnerID=8YFLogxK

U2 - 10.1007/s00259-005-1873-1

DO - 10.1007/s00259-005-1873-1

M3 - Article

VL - 33

SP - 156

EP - 163

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 2

ER -